Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
Healthy Weight Clinic, MQ Health, Sydney, New South Wales, Australia.
Oncology. 2022;100(6):344-353. doi: 10.1159/000524519. Epub 2022 Apr 11.
Weight gain during chemotherapy for breast cancer is a well-documented adverse effect. The purpose of this study was to investigate how multidisciplinary weight management involving endocrinology, dietitian, and exercise physiology care, in a real-life healthy weight clinic (HWC) would impact body weight and mass composition in breast cancer women post-adjuvant chemotherapy compared to a cohort of non-cancer women who have been matched by age, ethnicity, smoking, and menopausal status.
Body weight (kg), BMI (kg/m2), skeletal muscle mass (SMM %), fat mass (FM %), and waist circumference (cm) were collected at baseline of the first HWC appointment, 3 months after baseline, and 6 months after baseline. A total of 32 women were included, 11 in the breast cancer cohort and 21 in the control cohort, that matched inclusion and exclusion criteria based on a retrospective chart review from 28 July 2017 to 19 July 2021.
By 6 months, the breast cancer women had a mean weight change of -6.99 kg (SD = 3.87, p = 0.003, n = 11) and change in BMI by -2.72 kg/m2 (SD = 1.62, p = 0.004, n = 11). There was a change in SMM of 1.21% (SD = 0.73, p = 0.005, n = 11), a change in FM of -2.76% (SD = 1.33, p = 0.002, n = 11), and a change in waist circumference of -8.13 cm (SD = 4.21, p = 0.031, n = 3). By 6 months in the breast cancer cohort, there was a larger change in body weight in women who did not have MetS (-8.72 kg, SD = 2.41, n = 6) in comparison to women with MetS (-2.65 kg, SD = 3.75 kg, n = 3) (p = 0.045).
Findings indicate that multidisciplinary weight management has a positive role in early-stage breast cancer survival through improving body weight and mass composition. These results can add to the development of long-term treatment plans for survivors in order to shine a light on ways to reduce risk recurrence and chronic disease mortality.
乳腺癌化疗期间的体重增加是一种有据可查的不良反应。本研究的目的是调查涉及内分泌、营养师和运动生理学护理的多学科体重管理如何影响辅助化疗后的乳腺癌女性的体重和体成分，与经过年龄、种族、吸烟和绝经状态匹配的非癌症女性队列相比。
在第一次健康体重诊所（HWC）预约的基线、基线后 3 个月和基线后 6 个月时，收集体重（kg）、BMI（kg/m2）、骨骼肌量（SMM%）、体脂肪量（FM%）和腰围（cm）。共有 32 名女性入组，11 名来自乳腺癌组，21 名来自对照组，根据 2017 年 7 月 28 日至 2021 年 7 月 19 日的回顾性图表审查，基于纳入和排除标准匹配。
到 6 个月时，乳腺癌女性的平均体重变化为-6.99kg（SD=3.87，p=0.003，n=11），BMI 变化为-2.72kg/m2（SD=1.62，p=0.004，n=11）。SMM 变化了 1.21%（SD=0.73，p=0.005，n=11），FM 变化了-2.76%（SD=1.33，p=0.002，n=11），腰围变化了-8.13cm（SD=4.21，p=0.031，n=3）。在乳腺癌组中，6 个月时，没有代谢综合征（MetS）的女性体重变化更大（-8.72kg，SD=2.41，n=6），与有 MetS 的女性（-2.65kg，SD=3.75kg，n=3）相比（p=0.045）。
研究结果表明，多学科体重管理通过改善体重和体成分，对早期乳腺癌患者的生存有积极作用。这些结果可以为幸存者的长期治疗计划提供参考，以探索降低复发风险和慢性疾病死亡率的方法。
